696 related articles for article (PubMed ID: 18448375)
21. Evaluation of tri-combinant vaccine for feline herpesvirus, calicivirus and panleukopenia virus infections in Japanese native cats.
Yagami K; Furukawa T; Fukui M; Hamada H
Jikken Dobutsu; 1985 Jul; 34(3):287-94. PubMed ID: 2998830
[TBL] [Abstract][Full Text] [Related]
22. A dual-strain feline calicivirus vaccine stimulates broader cross-neutralization antibodies than a single-strain vaccine and lessens clinical signs in vaccinated cats when challenged with a homologous feline calicivirus strain associated with virulent systemic disease.
Huang C; Hess J; Gill M; Hustead D
J Feline Med Surg; 2010 Feb; 12(2):129-37. PubMed ID: 19836282
[TBL] [Abstract][Full Text] [Related]
23. Feline rhinotracheitis-calici-panleukopenia vaccine.
Turner EJ
Pediatrics; 1978 Apr; 61(4):675. PubMed ID: 208048
[No Abstract] [Full Text] [Related]
24. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
Grosenbaugh DA; Leard T; Pardo MC
J Am Vet Med Assoc; 2006 Mar; 228(5):726-7. PubMed ID: 16506935
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously.
Grosenbaugh DA; Leard T; Pardo MC; Motes-Kreimeyer L; Royston M
Vet Ther; 2004; 5(4):258-62. PubMed ID: 15719325
[TBL] [Abstract][Full Text] [Related]
26. Three-year duration of immunity for feline herpesvirus and calicivirus evaluated in a controlled vaccination-challenge laboratory trial.
Jas D; Frances-Duvert V; Vernes D; Guigal PM; Poulet H
Vet Microbiol; 2015 May; 177(1-2):123-31. PubMed ID: 25824128
[TBL] [Abstract][Full Text] [Related]
27. Immunisation with a combination of two complementary feline calicivirus strains induces a broad cross-protection against heterologous challenges.
Poulet H; Brunet S; Leroy V; Chappuis G
Vet Microbiol; 2005 Mar; 106(1-2):17-31. PubMed ID: 15737470
[TBL] [Abstract][Full Text] [Related]
28. Response of feral cats to vaccination at the time of neutering.
Fischer SM; Quest CM; Dubovi EJ; Davis RD; Tucker SJ; Friary JA; Crawford PC; Ricke TA; Levy JK
J Am Vet Med Assoc; 2007 Jan; 230(1):52-8. PubMed ID: 17199493
[TBL] [Abstract][Full Text] [Related]
29. Feline rhinotracheitis-calici vaccine and feline rhinotracheitis-calici-panleukopenia vaccine: field evaluation for safety.
Clark WB; Diegmann FG; McIntosh DK; Stiles JA; Slater EA
Vet Med Small Anim Clin; 1980 Mar; 75(3):415-20. PubMed ID: 6246668
[No Abstract] [Full Text] [Related]
30. Detection of protective antibody titers against feline panleukopenia virus, feline herpesvirus-1, and feline calicivirus in shelter cats using a point-of-care ELISA.
Digangi BA; Gray LK; Levy JK; Dubovi EJ; Tucker SJ
J Feline Med Surg; 2011 Dec; 13(12):912-8. PubMed ID: 21885311
[TBL] [Abstract][Full Text] [Related]
31. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
Hoover EA; Perigo NA; Quackenbush SL; Mathiason-DuBard CK; Overbaugh JM; Kloetzer WS; Elder JH; Mullins JI
J Am Vet Med Assoc; 1991 Nov; 199(10):1392-401. PubMed ID: 1666090
[TBL] [Abstract][Full Text] [Related]
32. Compatibility between a rabies vaccine and a combined vaccine against feline rhinotracheitis, FCV, FPLV and FeLV, and Chlamydophila felis.
Guiot AL; Cariou C; Krogmann V; Thibault JC; Poulet H
Vet Rec; 2008 May; 162(21):690-2. PubMed ID: 18503070
[No Abstract] [Full Text] [Related]
33. Effect of modified live or inactivated feline herpesvirus-1 parenteral vaccines on clinical and laboratory findings following viral challenge.
Summers SC; Ruch-Gallie R; Hawley JR; Lappin MR
J Feline Med Surg; 2017 Aug; 19(8):824-830. PubMed ID: 27432436
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of an inactivated vaccine for the prevention of rhinotracheitis, caliciviral disease, and panleukopenia in cats.
Povey RC; Koonse H; Hays MB
J Am Vet Med Assoc; 1980 Aug; 177(4):347-50. PubMed ID: 6256329
[TBL] [Abstract][Full Text] [Related]
35. Characterization of an avirulent FCV strain with a broad serum cross-neutralization profile and protection against challenge of a highly virulent vs feline calicivirus.
Rong S; Lowery D; Floyd-Hawkins K; King V
Virus Res; 2014 Aug; 188():60-7. PubMed ID: 24685673
[TBL] [Abstract][Full Text] [Related]
36. [Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H
Schweiz Arch Tierheilkd; 1994; 136(10):340-51. PubMed ID: 7801087
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of the Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV vaccines against infection with circulating feline Calicivirus.
Almeras T; Schreiber P; Fournel S; Martin V; Nicolas CS; Fontaine C; Lesbros C; Gueguen S
BMC Vet Res; 2017 Oct; 13(1):300. PubMed ID: 29017551
[TBL] [Abstract][Full Text] [Related]
38. Post-exposure treatment of cats with mouse-cat chimeric antibodies against feline herpesvirus type 1 and feline calicivirus.
Umehashi M; Imamura T; Akiyama S; Kimachi K; Tokiyoshi S; Mikami T
J Vet Med Sci; 2002 Nov; 64(11):1017-21. PubMed ID: 12499687
[TBL] [Abstract][Full Text] [Related]
39. Effect of high-dose ciclosporin on the immune response to primary and booster vaccination in immunocompetent cats.
Roberts ES; VanLare KA; Roycroft LM; King S
J Feline Med Surg; 2015 Feb; 17(2):101-9. PubMed ID: 24820998
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of autoantibodies that bind to kidney tissues in cats and association risk with antibodies to feline viral rhinotracheitis, calicivirus, and panleukopenia.
Songaksorn N; Petsophonsakul W; Pringproa K; Lampang KN; Sthitmatee N; Srifawattana N; Piyarungsri K; Thongkorn K
J Vet Sci; 2021 May; 22(3):e38. PubMed ID: 34056879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
